Xuan Wang, Hongming Pan, Jiuwei Cui, Xiao Chen, Won-Hee Yoon, Matteo S Carlino, Xin Li, Hui Li, Juan Zhang, Jingchao Sun, Jun Guo, Chuanliang Cui
Aim: Investigate TKI sitravatinib plus anti-PD-1 antibody tislelizumab in patients with unresectable/advanced/metastatic melanoma with disease progression on/after prior first-line anti-PD-(L)1 monotherapy. Methods: Open-label, multicenter, multicohort study (NCT03666143). Patients in the melanoma cohort (N = 25) received sitravatinib once daily plus tislelizumab every 3 weeks. The primary end point was safety and tolerability. Results: Treatment-emergent adverse events (TEAEs) occurred in all patients, with ≥grade 3 TEAEs in 52...
January 10, 2024: Immunotherapy